<DOC>
	<DOC>NCT02485015</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of Apatinib combined with cytokine-induced killer cell (CIK) vs Apatinib as the third line therapy for patients with advanced gastric cancer.</brief_summary>
	<brief_title>The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer</brief_title>
	<detailed_description>400 patients with stage Ⅳ Gastric Cancer,who had received surgery and chemotherapy,will be randomly divided into group A（receive Apatinib and CIK treatment ) or group B（just receive Apatinib),and the randomize ratio will be 1:1. Patients in group A will receive 3 cycles of CIK treatment (every 1 year) and Apatinib (continuous).Patients in group B will receive only Apatinib (continuous) .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>Patients who can accept curative operations 1870 years old Histologically confirmed with gastric cancer at stage Ⅳ Patients who can accept oral drugs; Eastern Cooperative Oncology Group (ECOG) performance status was 0 1. Hemoglobin＜8.0 g/dL,White blood cell ＜3 X 10^9/L;Platelet count ＜75 X 10^9/L; alanine aminotransferase, glutamicoxalacetic transaminase, blood urine nitrogen and creatinine more than normal limits on 3.0 times Known or suspected allergy to the investigational agent or any agent given in association with this trial Pregnant or lactating patients Known history of Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV) or TreponemaPallidun (TP) infection Patients who are suffering from serious autoimmune disease Patients who had used long time or are using immunosuppressant Patients who had active infection Patients who are suffering from serious organ dysfunction Patients who are suffering from other cancer Other situations that the researchers considered unsuitable for this study.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>CIK</keyword>
	<keyword>gastric cancer</keyword>
	<keyword>Apatinib</keyword>
</DOC>